Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!

Easy Branches

34/17 Moo 3 Chao fah west Road, Phuket, Thailand, Phuket

Call: 076 367 766

info@easybranches.com

Financial Personal

Aptose Reports Results for the Third Quarter 2024

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NAS

By: financialpost.com

Nov 08 2024
158
3233 Views

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML Read More

Related

Euro Sun Closes First Tranche of Previously Announced Private Placement Financing

ThreeD Capital Inc. Issues Early Warning Report in Connection with the Acquisition of Securities of AI/ML Innovations Inc.

Canoe EIT Income Fund Announces November 2024 Monthly Distribution and Quarterly Distribution on Preferred Units

Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2024 and Declares Quarterly Dividend

Koryx Copper Closes Second Tranche of Oversubscribed Private Placement for Gross Proceeds of $5.2 Million

Stallion Uranium Announces $2.6M Definitive Option Agreement for Horse Heaven Gold and Antimony Project

Spirit Blockchain Capital Inc. Provides Update on Non-Brokered Private Placement

NuLegacy Gold Provides Update

HYTN Announces Marketing Program

Aptose Reports Results for the Third Quarter 2024

Aduro Clean Technologies Announces Closing of US$4 Million Uplisting to Nasdaq

Emera Reports 2024 Third Quarter Financial Results

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Next

Euro Sun Closes First Tranche of Previously Announced Private Placement Financing